A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 12011292.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Interferon (IFN)-beta1a induction of neopterin and beta2-microglobulin (beta2-MG) were evaluated over 1 year in patients with MS. Neopterin and beta2-MG levels peaked 24 to 48 hours after weekly injections of IFNbeta1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNgamma expression and macrophage activation during IFNbeta-1a treatment. Predose levels of beta2-MG increased, the significance of which is as yet unclear.
Medical subject headings
- Interferon-beta
- Multiple Sclerosis, Relapsing-Remitting
- Neopterin
- beta 2-Microglobulin